Tilray (TLRY) AI Stock Analysis

• Market Cap: $1.50B
• Dividend Yield: N/A
• Average Volume (3M): 95.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 2.31%
• EPS Growth: -726.17%
• Country: US
• Employees: 2,650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 1,122,863,200
• 10 Day Avg. Volume: 62,304,959
• 30 Day Avg. Volume: 95,179,294
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.18
• Price to Sales (P/S): 0.34
• P/FCF Ratio: -2.97
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 1.39
• Enterprise Value/Gross Profit: 4.83
• Enterprise Value/Ebitda: -0.51
• 1Y Price Target: $1.95
• Price Target Upside: 51.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 49 Neutral
• Price Target: $1.50 ▲(16.28% Upside)

Tilray's overall stock score reflects significant financial challenges, with persistent losses and liquidity issues being the most impactful factors. While the earnings call provided some positive insights into revenue growth and debt reduction, the technical analysis and valuation remain weak, contributing to a lower overall score.

Positive Factors

International Expansion

Tilray's expansion into Panama through a joint venture enhances its international footprint, potentially increasing revenue and market share in the growing medical cannabis sector.

Revenue Growth

Consistent revenue growth, particularly in the cannabis segment, indicates strong demand and effective market strategies, supporting long-term business sustainability.

Balance Sheet Strength

Improved debt management and strong cash reserves enhance financial stability, providing Tilray with flexibility to invest in growth opportunities.

Negative Factors

Profitability Challenges

Ongoing profitability issues reflect operational inefficiencies and market challenges, potentially hindering Tilray's ability to sustain long-term growth.

Cash Flow Issues

Negative cash flows indicate poor cash conversion and liquidity challenges, which could limit Tilray's capacity to fund operations and strategic initiatives.

Lower Gross Margins

Declining gross margins suggest cost pressures and pricing challenges, which may impact profitability and competitive positioning in the long term.

Tilray Business Overview & Revenue Model

Company Description

Tilray, Inc. is a global leader in the cannabis industry, focusing on the production, distribution, and sale of medical and recreational cannabis products. Established in 2013, Tilray operates in various sectors, including pharmaceuticals, wellness, and consumer packaged goods. The company offers a diverse range of products, including dried cannabis, oils, and edibles, catering to both medical patients and adult consumers across several international markets.

How the Company Makes Money

Tilray generates revenue primarily through the sale of cannabis products, including dried flower, oils, and edibles, which are sold to both medical and recreational consumers. The company has established key revenue streams through its direct-to-consumer sales, partnerships with distributors and retailers, and international exports of medical cannabis products. Additionally, Tilray has formed strategic alliances with other companies in the cannabis and pharmaceutical sectors, which enhance its market reach and product offerings. The company's ongoing focus on research and development also positions it to capitalize on emerging trends in the cannabis market, contributing to its earnings potential.

Tilray Financial Statement Overview

Summary

Tilray's financial performance is weak, with significant losses and declining revenue. The income statement shows negative net profit margins and revenue contraction. The balance sheet indicates low leverage but negative returns, and cash flow analysis reveals liquidity issues with negative cash flows.

Income Statement

Tilray's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a gross profit margin of 28.77%, but the net profit margin is deeply negative at -278.12%, indicating substantial losses. Revenue growth is negative, suggesting a contraction in sales. Overall, the company is struggling with profitability and growth.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.15 in the TTM period, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not provided, but the available data suggests financial stability in terms of debt management, albeit with profitability concerns.

Cash Flow

Cash flow analysis highlights significant issues, with negative operating and free cash flows. The TTM data shows a free cash flow growth rate of -31.63%, indicating worsening cash generation. The operating cash flow to net income ratio is negative, reflecting poor cash conversion. Overall, the cash flow situation is concerning, with limited liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.08B	1.13B	1.07B	844.72M	792.12M	619.67M
Gross Profit	311.03M	330.11M	304.33M	197.95M	147.26M	148.77M
EBITDA	-2.97B	-2.92B	-99.25M	-1.72B	-310.61M	-297.41M
Net Income	-3.01B	-3.00B	-333.80M	-1.96B	-601.05M	-443.75M
Balance Sheet
Total Assets	2.08B	2.90B	5.91B	5.92B	6.87B	7.27B
Cash, Cash Equivalents and Short-Term Investments	264.83M	351.78M	354.98M	604.16M	524.29M	589.77M
Total Debt	231.29M	451.09M	527.75M	794.89M	786.36M	1.13B
Total Liabilities	561.99M	860.49M	1.22B	1.44B	1.27B	1.88B
Stockholders Equity	1.54B	2.07B	4.69B	4.47B	5.55B	5.38B
Cash Flow
Free Cash Flow	-119.70M	-174.98M	-81.96M	-17.37M	-266.39M	-100.93M
Operating Cash Flow	-83.01M	-129.81M	-42.11M	10.65M	-223.45M	-53.99M
Investing Cash Flow	28.48M	-64.11M	174.88M	-384.04M	-27.14M	55.67M
Financing Cash Flow	120.54M	183.20M	-102.45M	94.50M	161.60M	150.09M

Tilray Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.29
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLRY, the sentiment is Neutral. The current price of 1.29 is below the 20-day moving average (MA) of 1.56, below the 50-day MA of 1.41, and above the 200-day MA of 0.84, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 10.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TLRY.

Tilray Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDL	―	$553.41M	―	-8.30%	―	0.70%	15.62%
TLRY	―	$1.50B	―	-85.59%	―	2.31%	-726.17%
IMCC	―	$10.60M	―	-36.94%	―	2.17%	88.34%

Tilray Corporate Events

Tilray Brands Reports Record Revenue and Profitability

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company operating in the cannabis, beverage, and wellness industries, with a presence in Canada, the United States, Europe, Australia, and Latin America.

Tilray’s Earnings Call: Growth Amid Challenges

The recent earnings call for Tilray showcased a balanced sentiment, highlighting significant achievements in revenue growth and international expansion, while also addressing challenges in the Beverage segment and permitting delays in Portugal. The company demonstrated resilience and strategic foresight amidst these mixed outcomes.